New Cystic Fibrosis Data Reveals Lung Function Impact of Pulmonary Exacerbations

Strategic Insights -

Research at the University of Sydney has presented fresh insights into the characteristics, treatment, and lung function outcomes of pulmonary exacerbations in people with cystic fibrosis. The study, published in the European Respiratory Journal, reveals that the management of exacerbations remains a significant clinical burden, even in the context of modulator therapy. The researchers analyzed data from 982 people with cystic fibrosis, collected prospectively between 14 October 2020 and 9 October 2024, to understand the impact of pulmonary exacerbations on lung function.

Key Takeaways:

  • Pulmonary exacerbations pose a significant clinical burden on people with cystic fibrosis, regardless of modulator therapy.
  • In the study, 62% of pulmonary exacerbations occurred in people receiving modulator therapy.
  • The most frequently used antibiotics were intravenous tobramycin (63%) and piperacillin-tazobactam (43%).
  • Recovery patterns of lung function impairment during pulmonary exacerbations were consistent, regardless of baseline lung function, colonization, or modulator use.
  • The researchers concluded that there is a continued need for evidence to help clinicians balance treatment burden against the risk of irreversible loss of lung function.

Statistics:

  • 982 people with cystic fibrosis were enrolled in the study.
  • 593 pulmonary exacerbations were recorded in 323 individuals.
  • 62% of pulmonary exacerbations occurred in people receiving modulator therapy.
  • 41% of participants with spirometry at baseline and at Day 7 were below their baseline at Day 7 after commencing treatment.
  • 44% of participants with spirometry at baseline and at Day 60 were below their baseline at Day 60 after commencing treatment.

Sources:

  • "Characteristics, treatment, and lung function outcomes of pulmonary exacerbations in cystic fibrosis: insights from the BEAT-CF cohort." European Respiratory Journal, 2025:2501349.
  • European Respiratory Soc Journals Ltd, 442 Glossop Rd, Sheffield S10 2PX, England.
  • Wiley-Blackwell - www.wiley.com/
  • European Respiratory Journal - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1399-3003